Financials in USD. Standardized financial statements.
A compact view of how Jupiter Neurosciences, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $21,796 | $0 | $0 | $233,281 | $638,037 | $1.13M | $0 |
| Revenue Growth? | 0.0% | 0.0% | -100.0% | -63.4% | -43.3% | 0.0% | 0.0% |
| Cost of Revenue? | $4,231 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $17,565 | $0 | $0 | $233,281 | $638,037 | $1.13M | $0 |
| Gross Margin? | +80.6% | 0.0% | 0.0% | +100.0% | +100.0% | +100.0% | 0.0% |
| Operating Expenses? | $8.93M | $3.09M | $3.87M | $3.67M | $4.55M | $2.98M | $2.18M |
| Operating Income? | -$8.91M | -$3.09M | -$3.87M | -$3.43M | -$3.91M | -$1.85M | -$2.18M |
| EBITDA? | -$8.58M | -$2.19M | -$4.56M | -$4.22M | -$4.09M | -$1.64M | -$2.73M |
| Income Before Tax | -$8.64M | -$2.44M | -$4.78M | -$4.96M | -$4.20M | -$1.65M | -$3.05M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $179,168 | $0 | $0 |
| Net Income? | -$8.64M | -$2.44M | -$4.78M | -$4.96M | -$4.38M | -$1.65M | -$3.05M |
| EPS? | $-0.25 | $-0.08 | $-0.14 | $-0.15 | $-0.44 | $-0.19 | $-0.35 |
| Diluted EPS? | $-0.25 | $-0.08 | $-0.14 | $-0.15 | $-0.44 | $-0.19 | $-0.35 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality